Researchers at Brigham and Women’s Hospital have developed an innovative immunotherapeutic approach to treat melanoma brain metastases, significantly enhancing survival prospects. Published in Science Translational Medicine, the method employs a ‘twin stem cell model.’ One stem cell releases a cancer-fighting virus to reduce tumor growth, while a second, gene-edited stem cell—immune to the virus—releases proteins to bolster the immune response. This dual-action therapy aims to stymie tumor development and improve outcomes in models simulating human conditions. Given that patients with melanoma brain metastases typically have a survival time of just four to six months, this strategy represents a vital advancement in treatment options, particularly since traditional systemic therapies often fail to target brain metastases effectively. The researchers achieved success in preclinical trials, highlighting that locally delivered immunotherapies could revolutionize the treatment of brain metastases from various cancers beyond melanoma. The therapy can be administered via intrathecal injection, obviating the need for repeated treatment sessions. As the team prepares for upcoming Phase I clinical trials, they express optimism about the model’s potential to improve therapeutic efficacy in cancer treatment.
